Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

11-08-2016 | Gastric cancer | Article

Gastric biomarkers: a global review

Journal: World Journal of Surgical Oncology

Authors: Nick Baniak, Jenna-Lynn Senger, Shahid Ahmed, S. C. Kanthan, Rani Kanthan

Publisher: BioMed Central

Login to get access

Abstract

Background

Gastric cancer is an aggressive disease with a poor 5-year survival and large global burden of disease. The disease is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Despite the many prognostic, predictive, and therapeutic biomarkers investigated to date, gastric cancer continues to be detected at an advanced stage with resultant poor clinical outcomes.

Main body

This is a global review of gastric biomarkers with an emphasis on HER2, E-cadherin, fibroblast growth factor receptor, mammalian target of rapamycin, and hepatocyte growth factor receptor as well as sections on microRNAs, long noncoding RNAs, matrix metalloproteinases, PD-L1, TP53, and microsatellite instability.

Conclusion

A deeper understanding of the pathogenesis and biological features of gastric cancer, including the identification and characterization of diagnostic, prognostic, predictive, and therapeutic biomarkers, hopefully will provide improved clinical outcomes.
Literature
1.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
2.
Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4(7):156–69.PubMedCentralCrossRefPubMed
3.
Iarc . (2016). GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012 . Retrieved 19 July, 2016, from http://​globocan.​iarc.​fr/​Pages/​fact_​sheets_​cancer.​aspx. Accessed 4 Aug 2016.
4.
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65(2015):5–29.CrossRefPubMed
5.
Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 2008;43:256–64.CrossRefPubMed
6.
Hartgrink HH, Jansen EP, van Grieken NC, et al. Gastric cancer. Lancet. 2009;374:477–90.PubMedCentralCrossRefPubMed
7.
Ahn JR, Jung M, Kim C, et al. Prognosis of pN3 stage gastric cancer. Cancer Res Treat. 2009;41:73–9.PubMedCentralCrossRefPubMed
8.
Yasui W, Sentani K, Sakamoto N, et al. Molecular pathology of gastric cancer: research and practice. Pathol Res Pract. 2011;207:608–12.CrossRefPubMed
9.
Nobili S, Bruno L, Landini I, et al. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol. 2011;17:290–9.PubMedCentralCrossRefPubMed
10.
Sun M, Nie FQ, Wang ZX, et al. Involvement of lncRNA dysregulation in gastric cancer. Histol Histopathol. 2015;21:11655.
11.
Li PF, Chen SC, Xia T, et al. Non-coding RNAs and gastric cancer. World J Gastroenterol. 2014;20(18):5411–9.PubMedCentralCrossRefPubMed
12.
Shokal U, Sharma PC. Implication of microsatellite instability in human gastric cancers. Indian J Med Res. 2012;135(5):599–613.PubMedCentralPubMed
13.
Lauwers GY. Odze and Goldblum Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas (3rd Ed), Chapter 25, 707-721. Philadelphia: Elsevier, Saunders; 2015.
14.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef
15.
Durães C, Almeida GM, Seruca R, et al. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch. 2014;464(3):367–78.CrossRefPubMed
16.
Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics. 2012;75(11):3081–97.CrossRefPubMed
17.
Italiano A. Prognostic or predictive? It’s time to get back to definitions! J Clin Oncol. 2011;29(35):4718.CrossRefPubMed
18.
Fareed KR, Kaye P, Soomro IN, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 2009;58(1):127–43.CrossRefPubMed
19.
Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol. 2012;83(3):407–21.CrossRefPubMed
20.
Gallardo A, Lerma E, Escuin D, et al. Increased signaling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 2012;106:1367–73.PubMedCentralCrossRefPubMed
21.
Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.CrossRefPubMed
22.
Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57–65.PubMedCentralPubMed
23.
Allgayer H, Babic R, Gruetzner KU, et al. c‐erbB‐2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor‐associated protease systems. J Clin Oncol. 2000;18:2201–9.PubMed
24.
Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46:1949–59.CrossRefPubMed
25.
Chan DS, Campbell F, Edwards P, et al. Relative prognostic value of human epidermal growth factor receptor 2 (HER2) expression in operable oesophagogastric cancer. ISRN Surg. 2012;2012:804891.PubMedCentralCrossRefPubMed
26.
Phillips BE, Tubbs RR, Rice TW, et al. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2‐positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2013;26:299–304.CrossRefPubMed
27.
Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri‐operative chemotherapy in early oesophago‐gastric adenocarcinoma in the MAGIC trial. Ann Oncol. 2013;24:1253–61.CrossRefPubMed
28.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefPubMed
29.
Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63:839–42.CrossRefPubMed
30.
Zhou F, Li N, Jiang W, et al. Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol. 2012;10:274.PubMedCentralCrossRefPubMed
31.
Warneke VS, Behrens HM, Boger C, et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. 2013;24:725–33.CrossRefPubMed
32.
Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58(3):383–94.PubMedCentralCrossRefPubMed
33.
Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–50.CrossRefPubMed
34.
Yan B, Yau EX, Choo SN, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol. 2011;64(10):880–3.CrossRefPubMed
35.
Yang J, Luo H, Li Y, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2012;62(1):221–8.CrossRefPubMed
36.
Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59(5):822–31.PubMedCentralCrossRefPubMed
37.
Yoon HH, Shi Q, Sukov WR, et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012;30(32):3932–8.PubMedCentralCrossRefPubMed
38.
Kimura Y, Oki E, Yoshida A, et al. Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer. Anticancer Res. 2014;34(8):4207–12.PubMed
39.
Bilous M, Osamura RY, Rüschoff J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2010;41(2):304–5 (author reply 305-306).CrossRefPubMed
40.
NCCN guidelines gastric cancer, Principles of systemic therapy (GAST-E), 2012, < http://​www.​nccn.​org/​professionals/​physician_​gls/​f_​guidelines.​asp#site>. Accessed 4 Aug 2016.
41.
Fassan M, Mastracci L, Grillo F, et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology. 2012;61:769–76.CrossRefPubMed
42.
Gómez-Martin C, Garralda E, Echarri MJ, et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol. 2012;65(8):751–7.PubMedCentralCrossRefPubMed
43.
Xu CC, Yue L, Wei HJ, et al. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma. Pathol Res Pract. 2013;209(8):479–85.CrossRefPubMed
44.
Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Human Pathol. 2009;40:769–77.CrossRef
45.
Kunz PL, Mojtahed A, Fisher GA, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20:13–24.CrossRefPubMed
46.
Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Human Pathol. 2007;38:1386–93.CrossRef
47.
Yan SY, HuY FJG, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011;17:1501–6.PubMedCentralCrossRefPubMed
48.
Moelans CB, Milne AN, Morsink FH, et al. Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol (Dordrecht). 2011;34:89–95.CrossRef
49.
Fisher SB, Fisher KE, Squires 3rd MH, et al. HER2 in resected gastric cancer: is there prognostic value? J Surg Oncol. 2014;109(2):61–6.CrossRefPubMed
50.
Gomez-Martín C, Lopez-Rios F, Aparicio J, et al. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. Cancer Lett. 2014;351(1):30–40.CrossRefPubMed
51.
Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18:5992–6000.CrossRefPubMed
52.
Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17(1):34-42.
53.
Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT- 0116/SWOG9008 clinical trial. Ann Oncol. 2013;24(7):1754–61.PubMedCentralCrossRefPubMed
54.
Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656–62.CrossRefPubMed
55.
Sukawa Y, Yamamoto H, Nosho K, et al. Alterations in the human epidermal growth factor receptor 2‐phosphatidylinositol 3‐kinase‐v‐Akt pathway in gastric cancer. World J Gastroenterol. 2012;18:6577–86.PubMedCentralCrossRefPubMed
56.
Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8.CrossRefPubMed
57.
Bar-Sela G, Hershkovitz D, Haim N, et al. The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. Oncol Lett. 2013;5(2):559–63.PubMed
58.
Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100(3):487–93.PubMedCentralCrossRefPubMed
59.
Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371–9.CrossRefPubMed
60.
Kataoka Y, Okabe H, Yoshizawa A, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16:84–9.PubMedCrossRef
61.
Chua TC, Merret ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer. 2012;130:2845–56.CrossRefPubMed
62.
Power DG, Kelsen DP, Shah MA. Advanced gastric cancer—slow but steady progress. Cancer Treat Rev. 2010;36(5):384–92.CrossRefPubMed
63.
Boone JJM, Bhosle J, Tilby MJ, et al. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther. 2009;8:3015–23.CrossRefPubMed
64.
Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol. 2014;32:2039.PubMedCrossRef
65.
A study of trastuzumab emtansine versus taxane in patients with advanced gastric cancer https://​clinicaltrials.​gov/​ct2/​show/​NCT01641939. Accessed 4 Aug 2016.
66.
Anbiaee R, Mojir Sheibani K, Torbati P, et al. Abnormal expression of e-cadherin in gastric adenocarcinoma, and its correlation with tumor histopathology and helicobacter pylori infection. Iran Red Crescent Med J. 2013;15(3):218–22.PubMedPubMedCentralCrossRef
67.
Carneiro P, Fernandes MS, Figueiredo J, et al. E-cadherin dysfunction in gastric cancer—cellular consequences, clinical applications and open questions. FEBS Lett. 2012;586:2981–9.CrossRefPubMed
68.
Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci. 1999;24:73–6.CrossRefPubMed
69.
Chan AO. E-cadherin in gastric cancer. World J Gastroenterol. 2006;12:199–203.PubMedCentralCrossRefPubMed
70.
Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006;12:192–8.PubMedCentralCrossRefPubMed
71.
Corso G, Carvalho J, Marrelli D, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol. 2013;31(7):868–75.CrossRefPubMed
72.
Ferreira P, Oliveira MJ, Beraldi E, et al. Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Exp Cell Res. 2005;310(1):99–104.PubMedCrossRef
73.
Xin HW, Yang JH, Nguyen DM. Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma. Anticancer Res. 2013;33(6):2401–8.PubMed
74.
Blair VR. Familial gastric cancer: genetics, diagnosis, and management. Surg Oncol Clin N Am. 2012;21:35–56.PubMedCrossRef
75.
Barber M, Murrell A, Ito Y, et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol. 2008;216:295–306.CrossRefPubMed
76.
Schrader K, Huntsman D. Hereditary diffuse gastric cancer. Cancer Treat Res. 2010;155:33–63.CrossRefPubMed
77.
Oliveira C, Senz J, Kaurah P, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet. 2009;18:1545–55.PubMedCentralCrossRefPubMed
78.
Pinheiro H, Bordeira-Carrico R, Seixas S, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet. 2010;19:943–52.CrossRefPubMed
79.
Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203:681–7.CrossRefPubMed
80.
Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820–3.PubMedPubMedCentralCrossRef
81.
Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1:157–62.PubMedCrossRef
82.
Oliveira C, de Bruin J, Nabais S, et al. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene. 2004;23:2236–40.CrossRefPubMed
83.
Oliveira C, Sousa S, Pinheiro H, et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology. 2009;136:2137–48.PubMedCrossRef
84.
Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet. 2000;26:16–7.CrossRefPubMed
85.
Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348–53.CrossRefPubMed
86.
Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508–17.PubMedCentralCrossRefPubMed
87.
Lynch HT, Grady W, Suriano G, et al. Gastric cancer: new genetic developments. J Surg Oncol. 2005;90:114–33 [discussion: 33].PubMedCrossRef
88.
Uppal DS, Powell SM. Genetics/genomics/proteomics of gastric adenocarcinoma. Gastroenterol Clin North Am. 2013;42(2):241–60.PubMedCrossRef
89.
Corso G, Pedrazzani C, Pinheiro H, et al. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer. 2011;47:631–9.CrossRefPubMed
90.
Zhou YN, Xu CP, Han B, et al. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol. 2002;8(6):987–93.PubMedCentralCrossRefPubMed
91.
Guzman P, Araya J, Villaseca M, et al. Immunohistochemical expression of the E-cadherin-catenin complex in gastric cancer. Rev Med Chil. 2006;134(8):1002–9.PubMedCrossRef
92.
Stone J, Bevan S, Cunningham D, et al. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer. 1999;79:1935–7.PubMedPubMedCentralCrossRef
93.
Ascano JJ, Frierson Jr H, Moskaluk CA, et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol. 2001;14:942–9.CrossRefPubMed
94.
Graziano F, Arduini F, Ruzzo A, et al. Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res. 2004;10(8):2784–9.CrossRefPubMed
95.
Jawhari A, Jordan S, Poole S, et al. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology. 1997;112(1):46–54.CrossRefPubMed
96.
Gamboa-Dominguez A, Dominguez-Fonseca C, Chavarri-Guerra Y, et al. E-cadherin expression in sporadic gastric cancer from Mexico: exon 8 and 9 deletions are infrequent events associated with poor survival. Hum Pathol. 2005;36:29–35.CrossRefPubMed
97.
Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673–84.PubMedPubMedCentralCrossRef
98.
Singh SS, Yap WN, Arfuso F, et al. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: a reality for personalized medicine? World J Gastroenterol. 2015;21(43):12261–73.PubMedPubMedCentralCrossRef
99.
Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41(11):1649–54.PubMedCrossRef
100.
Lee J, van Hummelen P, Go C, et al. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One. 2012;7(6):e38892.PubMedCentralCrossRefPubMed
101.
Shi J, Yao D, Liu W, et al. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer. 2012;12:50.PubMedPubMedCentralCrossRef
102.
Barbi S, Cataldo I, De Manzoni G, et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon- selectivity is a signature of cancer type. J Exp Clin Cancer Res. 2010;29:32.PubMedPubMedCentralCrossRef
103.
Xu DZ, Geng QR, Tian Y, et al. Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer. 2010;10:536.PubMedPubMedCentralCrossRef
104.
Yu G, Wang J, Chen Y, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res. 2009;15(5):1821–9.PubMedCrossRef
105.
Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol. 2010;28:1904.PubMedCrossRef
106.
Yoon DH, Ryu MH, Park YS, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012;106:1039.PubMedPubMedCentralCrossRef
107.
Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31:3935.PubMedCrossRef
108.
Kim MA, Lee HS, Lee HE, et al. EGFR in gastric carcinomas, prognostic significance of protein over-expression and high gene copy number. Histopathology. 2008;52(6):738–46.PubMedCrossRef
109.
Kiyose S, Nagura K, Tao H, et al. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int. 2012;62(7):477–84.PubMedCrossRef
110.
Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomized, open-label phase 3 trial. Lancet Oncol. 2013;14:490.CrossRefPubMed
111.
Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481.PubMedPubMedCentralCrossRef
112.
Dragovich T, McCoy S, Fenoglio-Preiser C, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;24:4922–7.CrossRefPubMed
113.
Pietrantonio F, De Braud F, Da Prat V, et al. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res. 2013;33(4):1257–66.PubMed
114.
Graziano F, Galluccio N, Lorenzini P, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011;29(36):4789–95.PubMedCrossRef
115.
Lee J, Seo JW, Jun HJ, et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 2011;25(6):1517–24.PubMed
116.
Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29(36):4803–10.PubMedPubMedCentralCrossRef
117.
Lee HE, Kim MA, Lee HS, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012;107(2):325–33.PubMedPubMedCentralCrossRef
118.
Janjigian YY, Tang LH, Coit DG, et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(5):1021–7.PubMedPubMedCentralCrossRef
119.
Sehdev A, Catenacci DV. Gastroesophageal cancer: focus on epidemiology, classification, and staging. Discov Med. 2013;16(87):103–11.PubMed
120.
Shah MA, Cho JY, Huat IT, et al. Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). J Clin Oncol. 2015;33:suppl 3; abstr 2.CrossRef
121.
Jhawer M, Kindler H, Wainberg Z, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study. J Clin Oncol. 2009;27(15 Suppl):abstract 4502.
122.
Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011;1217:45–59.PubMedCrossRef
123.
Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 2015;6(5):561–9.PubMedCentralPubMed
124.
Muro K, Bang Y-J, Shankaran V, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab in KEYNOTE-012 (abstract). J Clin Oncol. 2015;33:suppl 3; abstr 3.
125.
Belyi VA, Ak P, Markert E, et al. The origins and evolution of the p53 family of genes. Cold Spring Harbor Perspectives in Biology. 2010;2(6):a001198.PubMedCentralCrossRefPubMed
126.
Bellini MF, Cadamuro AC, Succi M, et al. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012;2012:891961.PubMedPubMedCentralCrossRef
127.
Oki E, Zhao Y, Yoshida R, et al. The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract. Digestion. 2009;79(1):33–9.PubMedCrossRef
128.
Iwamatsu H, Nishikura K, Watanabe H, et al. Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinoma. Gastric Cancer. 2001;4(1):20–6.PubMedCrossRef
129.
Liu XP, Tsushimi K, Tsushimi M, et al. Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathol Int. 2001;51(6):440–4.PubMedCrossRef
130.
Fenoglio-Preiser CM, Wang J, Stemmermann GN, et al. TP53 and gastric carcinoma: a review. Human Mutation. 2003;21(3):258–70.PubMedCrossRef
131.
Lu HZ, Wu YP, Luo W, et al. Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOP-II alpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma. Zhonghua Zhong Liu Za Zhi. 2009;31(10):754–8.PubMed
132.
Corso G, Pedrazzani C, Marelli D, et al. Correlation of microsatellite instability at multiple loci with long term survival in advanced gastric carcinoma. Arch Surg. 2009;144:722–7.PubMedCrossRef
133.
Leung WK, Kim JJ, Kim JG, et al. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol. 2000;156:537–43.PubMedPubMedCentralCrossRef
134.
Pinto M, Oliveira C, Machado JC, et al. MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile. Lab Invest. 2000;80(12):1915–23.CrossRefPubMed
135.
Velho S, Fernandes MS, Leite M, et al. Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol. 2014;20(44):16433–42.PubMedCentralCrossRefPubMed
136.
Corso G, Velho S, Paredes J, et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer. 2011;47(3):443–51.CrossRefPubMed
137.
Oliveira C, Seruca R, Seixas M, et al. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different “target genes”: a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol. 1998;153(4):1211–9.PubMedCentralCrossRefPubMed
138.
Nakajima T, Akiyama Y, Shiraishi J, et al. Age-related hypermethylation of the hMLH1 promoter in gastric cancers. Int J Cancer. 2001;94:208–11.CrossRefPubMed
139.
Pedrazzani C, Corso G, Velho S, et al. Evidence of tumor microsatellite instability in gastric cancer with familial aggregation. Fam Cancer. 2009;8:215–20.CrossRefPubMed
140.
dos Santos NR, Seruca R, Constância M, et al. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology. 1996;110:38–44.CrossRefPubMed
141.
Seruca R, Santos NR, David L, et al. Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. Int J Cancer. 1995;64:32–6.CrossRefPubMed
142.
Beghelli S, de Manzoni G, Barbi S, et al. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery. 2006;139:347–56.CrossRefPubMed
143.
Han TS, Hur K, Xu G, et al. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut. 2015;64(2):203–14.CrossRefPubMed
144.
Su ZX, Zhao J, Rong ZH, et al. Diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer. Tumour Biol. 2014;35(12):12119–25.CrossRefPubMed
145.
Zhu X, Lv M, Wang H, et al. Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection: a systematic review and meta-analysis. Dig Dis Sci. 2014;59(5):911–9.CrossRefPubMed
146.
Zhu Z, Zhang X, Wang G, et al. Role of MICRORNAS in hepatocellular carcinoma. Hepat Mon. 2014;14:e18672.PubMedCentralCrossRefPubMed
147.
Huang D, Wang H, Liu R, et al. miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. J Cell Biochem. 2014;115(3):549–56.CrossRefPubMed
148.
Ma GJ, Gu RM, Zhu M, et al. Plasma post-operative miR-21 expression in the prognosis of gastric cancers. Asian Pac J Cancer Prev. 2013;14(12):7551–4.CrossRefPubMed
149.
Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3(9):e3148.PubMedCentralCrossRefPubMed
150.
Etheridge A, Lee I, Hood L, et al. Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011;717(1–2):85–90.PubMedCentralCrossRefPubMed
151.
Vosa U, Vooder T, Kolde R, et al. Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 2013;132:2884–93.CrossRefPubMed
152.
Gong X, Wu R, Wang H, et al. Evaluating the consistency of differential expression of microRNA detected in human cancers. Mol Cancer Ther. 2011;10:752–60.CrossRefPubMed
153.
Shrestha S, Hsu SD, Huang WY, et al. A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 2014;3(4):878–88.PubMedCentralCrossRefPubMed
154.
Liu HS, Xiao HS. MicroRNAs as potential biomarkers for gastric cancer. World J Gastroenterol. 2014;20(34):12007–17.PubMedCentralCrossRefPubMed
155.
Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med. 2014;16:e1.PubMedCentralCrossRefPubMed
156.
Fang XY, Pan HF, Leng RX, et al. Long noncoding RNAs: novel insights into gastric cancer. Cancer Lett. 2015;356(2 Pt B):357–66.CrossRefPubMed
157.
Kaikkonen MU, Lam MT, Glass CK. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res. 2011;90:430–40.PubMedCentralCrossRefPubMed
158.
Yang L, Froberg JE, Lee JT. Long noncoding RNAs: fresh perspectives into the RNA world. Trends Biochem Sci. 2014;39:35–43.CrossRefPubMed
159.
Kornienko AE, Guenzl PM, Barlow DP, et al. Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 2013;11:59.PubMedCentralCrossRefPubMed
160.
Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146:353–8.PubMedCentralCrossRefPubMed
161.
Song H, Sun W, Ye G, et al. Long non-coding RNA expression profile in human gastric cancer and its clinical significances. J Transl Med. 2013;11:225.PubMedCentralCrossRefPubMed
162.
Sampieri CL, León-Córdoba K, Remes-Troche JM. Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers. J Cancer Res Ther. 2013;9(3):356–63.CrossRefPubMed
163.
Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115:3719–27.CrossRefPubMed
164.
Swarnakar S, Paul S, Singh LP, et al. Matrix metalloproteinases in health and disease: regulation by melatonin. J Pineal Res. 2011;50(1):8–20.CrossRefPubMed
165.
Koskensalo S, Mrena J, Wiksten JP, et al. MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010;31(3):149–55.CrossRefPubMed
166.
Shi M, Liu D, Duan H, et al. Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. Mol Cancer. 2010;9:269.PubMedCentralCrossRefPubMed
167.
Al-Batran SE, Pauligk C, Wirtz R, et al. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Ann Oncol. 2012;23(7):1699–705.CrossRefPubMed
168.
Chang WJ, Du Y, Zhao X, et al. Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 2014;20(16):4586–96.PubMedCentralCrossRefPubMed
169.
Long ZW, Wang JL, Wang YN. Matrix metalloproteinase-7 mRNA and protein expression in gastric carcinoma: a meta-analysis. Tumour Biol. 2014;35(11):11415–26.CrossRefPubMed
170.
Yonemura Y, Fujimura T, Ninomiya I, et al. Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res. 2001;7:1647–53.PubMed
171.
Wu CY, Wu MS, Chiang EP, et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res. 2007;13:2054–60.CrossRefPubMed
172.
Chu D, Zhang Z, Li Y, et al. Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer. 2011;129(4):887–95.CrossRefPubMed
173.
Wu T, Li Y, Lu J, et al. Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer. Med Oncol. 2013;30(1):323.CrossRefPubMed
174.
Wu KP, Li Q, Lin FX, et al. MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies. Tumour Biol. 2014;35(12):12489–95.CrossRefPubMed
175.
Peng CW, Wang LW, Fang M, et al. Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinical outcomes of gastric cancer. J Transl Med. 2013;11:153.PubMedCentralCrossRefPubMed
176.
Shim KN, Jung SA, Joo YH, et al. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol. 2007;42:120–8.CrossRefPubMed
177.
He L, Chu D, Li X, et al. Matrix metalloproteinase-14 is a negative prognostic marker for patients with gastric cancer. Dig Dis Sci. 2013;58:1264–70.CrossRefPubMed
178.
Bramhall S, Hallissey M, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002;86:1864–70.PubMedCentralCrossRefPubMed
179.
Rugge M, Capelle LG, Fassan M. Individual risk stratification of gastric cancer: evolving concepts and their impact on clinical practice. Best Pract Res Clin Gastroenterol. 2014;28(6):1043–53.CrossRefPubMed
180.
Riquelme I, Saavedra K, Espinoza JA, et al. Molecular classification of gastric cancer: towards a pathway-driven targeted therapy. Oncotarget. 2015;6(28):24750–79.PubMedCentralCrossRefPubMed
181.
Wadhwa R, Song S, Lee JS, et al. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10(11):643–55.PubMedCentralCrossRefPubMed
182.
Ali SM, Sanford EM, Klempner SJ. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist. 2015;20(5):499–507.PubMedCentralCrossRefPubMed